Is ocular toxicity expected in chloroquine/hydroxychloroquine prescription as a therapeutic or prophylactic option in COVID-19?
CONCLUSION: This study recommended ophthalmic evaluation before CQ/HCQ prescription for treatment or prophylaxis of COVID-19 only in preexisting maculopathy.
PMID: 32814539 [PubMed - as supplied by publisher]
Source: Recent Patents on Anti-Infective Drug Discovery - Category: Infectious Diseases Tags: Recent Pat Antiinfect Drug Discov Source Type: research
More News: China Health | Coronavirus | COVID-19 | Emergency Medicine | Hydroxychloroquine | Infectious Diseases | International Medicine & Public Health | Opthalmology | Pandemics | Pneumonia | Poisoning | Study | Toxicology | Vitamin A